120
Views
14
CrossRef citations to date
0
Altmetric
Original Article

Rituximab Toxicity in Patients with Peripheral Blood Malignant B-cell Lymphocytosis

, , , , &
Pages 1329-1337 | Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (6)

Dimitrios Kalkanis, Alexandra Stefanovic, Fabio Paes, Maricer P. Escalon, Aldo Serafini & Izidore S. Lossos. (2009) [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. Leukemia & Lymphoma 50:6, pages 904-911.
Read now
Xin Liu, Xiao-Nan Hong, Ya-Jia Gu, Bi-Yun Wang, Zhi-Guo Luo & Junning Cao. (2008) Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leukemia & Lymphoma 49:9, pages 1778-1783.
Read now
Gerhard Held, Viola Pöschel & Michael Pfreundschuh. (2006) Rituximab for the treatment of diffuse large B-cell lymphomas. Expert Review of Anticancer Therapy 6:8, pages 1175-1186.
Read now
Doru Alexandrescu, Janice Dutcher, Kevin O'Boyle, Mehmet Albulak, Stanley Oiseth & Peter Wiernik. (2004) Fatal Intra-Alveolar Hemorrhage After Rituximab in a Patient with non-Hodgkin Lymphoma. Leukemia & Lymphoma 45:11, pages 2321-2325.
Read now
Morie A Gertz, Montserrat Rue, Emily Blood, Lynne S Kaminer, David H Vesole & Philip R Greipp. (2004) Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98). Leukemia & Lymphoma 45:10, pages 2047-2055.
Read now

Articles from other publishers (8)

Yuchen Wu, Xuefei Sun, Jing Liu, Jun Qian, Xueyan Bai, Yuedan Chen & Yuanbo Liu. (2018) Interstitial pneumonitis during rituximab-containing chemotherapy for primary central nervous system lymphomas: a case report and review of literature. Chinese Neurosurgical Journal 4:1.
Crossref
Kimberly Keefer, Regis Bender, Jason Liao, Jeffrey Sivik & Andry Van de Louw. (2018) Characteristics of pulmonary complications in non-Hodgkin’s lymphoma patients treated with rituximab-containing chemotherapy and impact on survival. Annals of Hematology 97:12, pages 2373-2380.
Crossref
Frederico F Souza, Andrew Smith, Cyrillo Araujo, Jyothi Jagannathan, Ciaran Johnston, Kevin O’Regan, Atul Shinagare & Nikhil Ramaiya. (2014) New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know. Cancer Imaging 14:1.
Crossref
P. Bose & O. Qubaiah. (2011) A review of tumour lysis syndrome with targeted therapies and the role of rasburicase. Journal of Clinical Pharmacy and Therapeutics 36:3, pages 299-326.
Crossref
Robert O. Dillman. (2011) Cancer Immunotherapy. Cancer Biotherapy and Radiopharmaceuticals 26:1, pages 1-64.
Crossref
Aisha Shaikh, Thomas M. Habermann, Mary E. Fidler, Shaji Kumar & Nelson Leung. (2008) Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström’s macroglobulinemia. Clinical and Experimental Nephrology 12:4, pages 292-295.
Crossref
I. Dimopoulou, A. Bamias, P. Lyberopoulos & M.A. Dimopoulos. (2006) Pulmonary toxicity from novel antineoplastic agents. Annals of Oncology 17:3, pages 372-379.
Crossref
. (2002) Current Awareness. Pharmacoepidemiology and Drug Safety 11:5, pages 421-436.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.